Professional Documents
Culture Documents
com/viewarticle/807869_print
www.medscape.com
The testing device is called the Neuropsychiatric EEG-Based Assessment Aid (NEBA) System. The noninvasive test, based on electroencephalogram technology, computes the ratio of theta and beta brain
waves in 15 to 20 minutes. Children and adolescents with ADHD have a higher theta-beta ratio than those who do not have the disorder.
Together with a complete medical and psychological workup, the NEBA System can help confirm a diagnosis of ADHD or a decision to focus further testing on ADHD or other conditions with similar symptoms,
according to the FDA.
"The NEBA System along with other clinical information may help healthcare providers more accurately determine if ADHD is the cause of a behavioral problem," Christy Foreman, director of the Office of
Device Evaluation at the FDA's Center for Devices and Radiological Health, said in a news release.
The agency based its decision to approve the NEBA System in part on a clinical study of 275 children and adolescents with attention or behavioral issues. Clinicians evaluated all of them using the new
brain-wave test along with standard diagnostic protocols and physical exams. An independent panel of ADHD experts reviewed the findings to determine whether each patient satisfied the criteria for ADHD or
another condition. The study showed that adding the brain-wave test to a clinical assessment helped clinicians make a more accurate ADHD diagnosis than if they had performed only the clinical assessment.
More information on the FDA decision to approve the NEBA System is available on the agency Web site.
Cite this article: First Brain-Wave Test for ADHD Approved by FDA. Medscape. Jul 15, 2013.
1 de 1 17-07-2013 12:45